Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report

Oliver Gautschi; Joachim Diebold

doi:10.1016/j.jtocrr.2021.100162

Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report

JTO Clin Res Rep. 2021 Mar 9;2(4):100162. doi: 10.1016/j.jtocrr.2021.100162. eCollection 2021 Apr.

Authors

Oliver Gautschi¹, Joachim Diebold¹

Affiliation

¹ Cantonal Hospital Lucerne, Cancer Center, Lucerne, Switzerland.

Abstract

We previously published in the Journal of Thoracic Oncology the case of a patient with EGFR and MET-driven lung cancer and extracranial response to capmatinib and osimertinib. Here, we report on a second patient treated with the same combination, revealing complete and durable intracranial response. Adding capmatinib to osimertinib seems to be an effective salvage therapy for patients with EGFR-mutant lung cancer and acquired MET amplification.

Keywords: Capmatinib; Case report; Lung cancer; Osimertinib; Targeted therapy.

Publication types

Case Reports